MAX Chat
Share chart Neurocrine Biosciences
Extended chart
Simple chart
Main settings
Currency
usd
Dividend income of JSC
0
IPO Time
1996-05-23
ISIN
US64125C1099
Industry
Biotechnology
Report Currency
usd
Sector
Health Care
Website
Grade
Underestimation
| Title | Value | Grade |
| P/S | 6.03 | 1 |
| P/BV | 5.49 | 2 |
| P/E | 41.64 | 4 |
Efficiency
| Title | Value | Grade |
| ROA | 9.79 | 3 |
| ROE | 14.16 | 4 |
| ROIC | 5.01 | 2 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 0.7114 | 9 |
| Debt/Ratio | 0.1224 | 10 |
| Debt/Equity | 0.436 | 10 |
Growth impulse
| Title | Value | Grade |
| Revenue, bln, % | 124.31 | 10 |
| Ebitda, % | 95.33 | 9 |
| EPS, % | -20.88 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 141.87 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 143.8 $ | 141.25 $ | 144.17 $ | -1.34 % | 0 % | 0 % |
| Month | 135.43 $ | 131.31 $ | 144.17 $ | +4.76 % | 0 % | 0 % |
| Three month | 134.92 $ | 123.98 $ | 144.17 $ | +5.15 % | 0 % | 0 % |
| Half a year | 121.61 $ | 87.54 $ | 144.17 $ | +16.66 % | 0 % | 0 % |
| Year | 139.03 $ | 87.54 $ | 153.29 $ | +2.04 % | 0 % | 0 % |
| 3 years | 107.99 $ | 87.54 $ | 153.29 $ | +31.37 % | 0 % | 0 % |
| 5 years | 96.01 $ | 73.55 $ | 153.29 $ | +47.77 % | 0 % | 0 % |
| 10 years | 52.7 $ | 32.19 $ | 153.29 $ | +169.2 % | 0 % | 0 % |
| Year to date | 110.75 $ | 87.54 $ | 153.29 $ | +28.1 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
| PSYK ETF | 4.51 | 0 | 0.75 |
| VictoryShares Nasdaq Next 50 ETF | 1.2271 | 0.8926 | 0.18 |
| Future Tech ETF | 1.15959 | 479.5 | 0.35 |
| Principal Healthcare Innovators ETF | 1.15959 | -3.92 | 0.35 |
| GraniteShares XOUT U.S. Large Cap ETF | 0.80826 | -28.16 | 0.60 |
| First Trust Mid Cap US Equity Select ETF | 0.787 | -10.36 | 0.60 |
| Donoghue Forlines Innovation ETF | 0.55247 | 9.72 | 0.69 |
| Syntax Stratified MidCap ETF | 0.36602 | -0.3413 | 0.35 |
| FCF US Quality ETF | 0.29911 | 0.8846 | 0.59 |
| iShares Morningstar Mid-Cap Growth ETF | 0.22135 | 398.96 | 0.06 |
| iShares Morningstar Mid-Cap ETF | 0.1109 | 229.67 | 0.04 |
| iShares Morningstar Large-Cap Growth ETF | 0.04883 | 217.39 | 0.04 |
| iShares Factors US Growth Style ETF | 0.03532 | -8.76 | 0.25 |
| Columbia U.S. ESG Equity Income ETF | 0.02679 | -3.61 | 0.35 |
| iShares Morningstar Large-Cap ETF | 0.02418 | 181.01 | 0.03 |
| 0.76 | 97.52 | 0.35 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Matthew C. Abernethy | Chief Financial Officer | 1.04M | 1980 (45 years) |
| Mr. Eric S. Benevich | Chief Commercial Officer | 805k | 1965 (60 years) |
| Jane Sorensen | Head of Investor Relations | N/A | |
| Ms. Julie S. Cooke | Chief Human Resources Officer | N/A | 1966 (59 years) |
| Dr. Kevin C. Gorman Ph.D. | CEO & Director | 1.9M | 1958 (67 years) |
| Dr. Jude Onyia Ph.D. | Chief Scientific Officer | 621.66k | 1964 (61 year) |
| Dr. Eiry Wyn Roberts M.D. | Chief Medical Officer | 1.04M | 1964 (61 year) |
| Mr. Darin M. Lippoldt Esq. | Chief Legal Officer & Corporate Secretary | 921.01k | 1966 (59 years) |
| Mr. Kyle W. Gano Ph.D. | Chief Business Development & Strategy Officer | 921.52k | 1973 (52 years) |
| Mr. David Warren Boyer | Chief Corporate Affairs Officer | N/A | 1980 (45 years) |
About company
Address: United States, San Diego, 12780 El Camino Real - Open in google maps, Open in yandex maps
Website: http://www.neurocrine.com
Website: http://www.neurocrine.com
